These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7160397)

  • 1. Effects of prenalterol in congestive heart failure.
    Hjalmarson A; Abelardo N; Waagstein E
    Eur Heart J; 1982 Dec; 3 Suppl D():115-21. PubMed ID: 7160397
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience of a new inotropic agent--Prenalterol--in hypotension and heart failure.
    Reiz S; Waagstein F; Hjalmarson A
    Clin Cardiol; 1980 Apr; 3(2):96-105. PubMed ID: 6104553
    [No Abstract]   [Full Text] [Related]  

  • 3. Hemodynamic effects of intravenous prenalterol in patients on long-term digoxin therapy for congestive heart failure.
    Dahlström U; Karlsson E; Wranne B
    Eur Heart J; 1982 Aug; 3(4):331-8. PubMed ID: 7128622
    [No Abstract]   [Full Text] [Related]  

  • 4. Contractile, coronary, and metabolic effects of the acute and long-term treatment of cardiac failure with prenalterol.
    Strauer BE; Bohn I; Hahn B; Kment A; Motz U
    J Cardiovasc Pharmacol; 1984; 6(3):491-8. PubMed ID: 6202977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance.
    Wahr DW; Swedberg K; Rabbino M; Hoyle MJ; Curran D; Parmley WW; Chatterjee K
    Am J Med; 1984 Jun; 76(6):999-1005. PubMed ID: 6731471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.
    Tweddel AC; Murray RG; Pearson D; Martin W; Hutton I
    Br Heart J; 1982 Apr; 47(4):375-80. PubMed ID: 6121566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical use of inotropes in cardiac failure: dopamine, dobutamine, prenalterol and pirbuterol.
    Rae AP; Tweddel AC; Hutton I
    Herz; 1983 Feb; 8(1):23-33. PubMed ID: 6832690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure.
    Dahlström U; Graffner C; Jonsson U; Hoffmann KJ; Karlsson E; Lagerström PO
    Eur J Clin Pharmacol; 1983; 24(4):495-502. PubMed ID: 6861864
    [No Abstract]   [Full Text] [Related]  

  • 9. [Electrophysiologic effects of prenalterol On sinus function in coronary disease patients].
    Bolognesi R; Cucchini F; Giacometti P; Sartori M; Zeppellini R; Javernaro A; Potenza D
    Cardiologia; 1982; 27(2):219-22. PubMed ID: 6927435
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute effects of beta 1 agonism with prenalterol on catecholamine circulating levels in patients with congestive heart failure.
    Corea L; Bentivoglio M; Verdecchia P; Provvidenza M
    G Ital Cardiol; 1983 Nov; 13(11):330-4. PubMed ID: 6141975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term effect of a new beta-agonist prenalterol in patients with severe congestive heart failure (author's transl)].
    Lambertz H; Erbel R; Meyer J; Schweizer P; Effert S
    Z Kardiol; 1982 Jan; 71(2):65-74. PubMed ID: 6122313
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of prenalterol administered orally in patients with congestive heart failure.
    Hjalmarson A; Abelardo N; Caidahl K; Reyes C; Waagstein F; Wallentin I; Wikstrand J; Estrada-Yamamoto M
    Acta Med Scand Suppl; 1982; 659():201-20. PubMed ID: 6127890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute haemodynamic effects of oral prenalterol in severe heart failure.
    Petch MC; Wisbey C; Ormerod O; Scott C; Goodfellow RM
    Br Heart J; 1984 Jul; 52(1):49-52. PubMed ID: 6146324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short and long-term effects of hydralazine and combined hydralazine and prenalterol therapy in patients with congestive heart failure.
    Drexler H; Löllgen H; Just H
    Acta Med Scand Suppl; 1982; 659():315-24. PubMed ID: 6127898
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute haemodynamic effects of intravenous amrinone in chronic congestive heart failure.
    Bahl VK; Khalilullah M
    Indian Heart J; 1984; 36(6):369-74. PubMed ID: 6535755
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
    Currie PJ; Kelly MJ; Middlebrook K; Federman J; Sainsbury E; Ashley J; Pitt A
    Br Heart J; 1984 May; 51(5):530-8. PubMed ID: 6326784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results with prenalterol in patients with heart failure.
    Waagstein F; Reiz S; Ariniego R; Hjalmarson A
    Am Heart J; 1981 Sep; 102(3 Pt 2):548-54. PubMed ID: 7270401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioselectivity of dobutamine and prenalterol in the pentobarbital anesthetized dog.
    Strosberg AM; Montgomery W
    Proc West Pharmacol Soc; 1981; 24():83-7. PubMed ID: 7255492
    [No Abstract]   [Full Text] [Related]  

  • 19. Prenalterol as a selective cardiostimulant: differences between organ and receptor selectivity.
    Kenakin TP
    J Cardiovasc Pharmacol; 1985; 7(1):208-10. PubMed ID: 2580145
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-dependent haemodynamic response to prenalterol in patients with congestive heart failure.
    Leinberger H; Mäurer W; Haueisen H; Schuler G; Kübler W
    Acta Med Scand Suppl; 1982; 659():299-306. PubMed ID: 6127896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.